Drug
Vatiquinone
Vatiquinone: highest development phase Phase 3, developed by PTC Therapeutics. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- PTC Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vatiquinone NCT05218655 | Phase 3 | Inherited Mitochondrial Disease |
| Vatiquinone NCT07681713 | Phase 3 | Friedreich's Ataxia |
| Vatiquinone NCT05515536 | Phase 3 | Friedreich Ataxia |
| Vatiquinone NCT04577352 | Phase 2/3 | Friedreich Ataxia |
| Vatiquinone NCT04378075 | Phase 2/3 | Mitochondrial Diseases |
| Vatiquinone NCT05485987 | Phase 2 | Friedreich Ataxia |
Latest
No recent events.
Follow Vatiquinone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.